Emerald Advisers, LLC Curis Inc Transaction History

Emerald Advisers, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 29, 2022	SELL	$0.71 - $2.43 $1.57 Million - $5.38 Million	-2,215,905 Closed	0 $0
Q1 2022 Apr 29, 2022	BUY	$2.31 - $5.13 $472,921 - $1.05 Million	204,728 Added 10.18%	2,215,905 $5.27 Million
Q4 2021 Feb 02, 2022	SELL	$4.45 - $8.09 $112,674 - $204,838	-25,320 Reduced 1.24%	2,011,177 $9.57 Million
Q3 2021 Oct 28, 2021	BUY	$6.94 - $8.85 $449,642 - $573,391	64,790 Added 3.29%	2,036,497 $15.9 Million
Q2 2021 Jul 29, 2021	BUY	$7.45 - $16.27 $1.31 Million - $2.86 Million	175,796 Added 9.79%	1,971,707 $15.9 Million
Q1 2021 Apr 29, 2021	BUY	$8.78 - $12.8 $1.98 Million - $2.88 Million	225,090 Added 14.33%	1,795,911 $20.3 Million
Q4 2020 Jan 29, 2021	BUY	$1.08 - $8.2 $1.7 Million - $12.9 Million	1,570,821 New	1,570,821 $12.9 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.